BACKGROUND:By the year 2030, 3.48 million older U.S. adults are projected to undergo total knee arthroplasty (TKA). Following this surgery, considerable muscle atrophy occurs, resulting in decreased strength and impaired functional mobility. Essential amino acids (EAAs) have been shown to attenuate muscle loss during periods of reduced activity and may be beneficial for TKA patients. METHODS: We used a double-blind, placebo-controlled, randomized clinical trial with 28 older adults undergoing TKA. Patients were randomized to ingest either 20 g of EAAs (n = 16) or placebo (n = 12) twice daily between meals for 1 week before and 2 weeks after TKA. At baseline, 2 weeks, and 6 weeks after TKA, an MRI was performed to determine mid-thigh muscle and adipose tissue volume. Muscle strength and functional mobility were also measured at these times. RESULTS:TKA patients receivingplacebo exhibited greater quadriceps muscle atrophy, with a -14.3 ± 3.6% change from baseline to 2 weeks after surgery compared with -3.4 ± 3.1% for the EAA group (F = 5.16, P = 0.036) and a -18.4 ± 2.3% change from baseline to 6 weeks after surgery for placebo versus -6.2 ± 2.2% for the EAA group (F = 14.14, P = 0.001). EAAs also attenuated atrophy in the nonoperated quadriceps and in the hamstring and adductor muscles of both extremities. The EAA group performed better at 2 and 6 weeks after surgery on functional mobility tests (all P < 0.05). Change in quadriceps muscle atrophy was significantly associated with change in functional mobility (F = 5.78, P = 0.021). CONCLUSION:EAA treatment attenuated muscle atrophy and accelerated the return of functional mobility in older adults following TKA. TRIAL REGISTRATION: Clinicaltrials.gov NCT00760383.
RCT Entities:
BACKGROUND: By the year 2030, 3.48 million older U.S. adults are projected to undergo total knee arthroplasty (TKA). Following this surgery, considerable muscle atrophy occurs, resulting in decreased strength and impaired functional mobility. Essential amino acids (EAAs) have been shown to attenuate muscle loss during periods of reduced activity and may be beneficial for TKA patients. METHODS: We used a double-blind, placebo-controlled, randomized clinical trial with 28 older adults undergoing TKA. Patients were randomized to ingest either 20 g of EAAs (n = 16) or placebo (n = 12) twice daily between meals for 1 week before and 2 weeks after TKA. At baseline, 2 weeks, and 6 weeks after TKA, an MRI was performed to determine mid-thigh muscle and adipose tissue volume. Muscle strength and functional mobility were also measured at these times. RESULTS: TKA patients receiving placebo exhibited greater quadriceps muscle atrophy, with a -14.3 ± 3.6% change from baseline to 2 weeks after surgery compared with -3.4 ± 3.1% for the EAA group (F = 5.16, P = 0.036) and a -18.4 ± 2.3% change from baseline to 6 weeks after surgery for placebo versus -6.2 ± 2.2% for the EAA group (F = 14.14, P = 0.001). EAAs also attenuated atrophy in the nonoperated quadriceps and in the hamstring and adductor muscles of both extremities. The EAA group performed better at 2 and 6 weeks after surgery on functional mobility tests (all P < 0.05). Change in quadriceps muscle atrophy was significantly associated with change in functional mobility (F = 5.78, P = 0.021). CONCLUSION:EAA treatment attenuated muscle atrophy and accelerated the return of functional mobility in older adults following TKA. TRIAL REGISTRATION: Clinicaltrials.gov NCT00760383.
Authors: Steven Kurtz; Fionna Mowat; Kevin Ong; Nathan Chan; Edmund Lau; Michael Halpern Journal: J Bone Joint Surg Am Date: 2005-07 Impact factor: 5.284
Authors: Bret H Goodpaster; Seok Won Park; Tamara B Harris; Steven B Kritchevsky; Michael Nevitt; Ann V Schwartz; Eleanor M Simonsick; Frances A Tylavsky; Marjolein Visser; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2006-10 Impact factor: 6.053
Authors: Catherine R Mikus; Leryn J Boyle; Sarah J Borengasser; Douglas J Oberlin; Scott P Naples; Justin Fletcher; Grace M Meers; Meghan Ruebel; M Harold Laughlin; Kevin C Dellsperger; Paul J Fadel; John P Thyfault Journal: J Am Coll Cardiol Date: 2013-04-10 Impact factor: 24.094
Authors: Whitney Meier; Ryan L Mizner; Robin L Marcus; Leland E Dibble; Christopher Peters; Paul C Lastayo Journal: J Orthop Sports Phys Ther Date: 2007-12-14 Impact factor: 4.751
Authors: M J Rennie; A Selby; P Atherton; K Smith; V Kumar; E L Glover; S M Philips Journal: Scand J Med Sci Sports Date: 2009-06-23 Impact factor: 4.221
Authors: Leigh Breen; Keith A Stokes; Tyler A Churchward-Venne; Daniel R Moore; Stephen K Baker; Kenneth Smith; Philip J Atherton; Stuart M Phillips Journal: J Clin Endocrinol Metab Date: 2013-04-15 Impact factor: 5.958
Authors: Daniel K Fox; Scott M Ebert; Kale S Bongers; Michael C Dyle; Steven A Bullard; Jason M Dierdorff; Steven D Kunkel; Christopher M Adams Journal: Am J Physiol Endocrinol Metab Date: 2014-06-03 Impact factor: 4.310
Authors: Jonathan B Muyskens; Douglas M Foote; Nathan J Bigot; Lisa A Strycker; Keith Smolkowski; Tessa K Kirkpatrick; Brick A Lantz; Steven N Shah; Craig G Mohler; Brian A Jewett; Erin C Owen; Hans C Dreyer Journal: J Appl Physiol (1985) Date: 2019-07-25
Authors: Jared M Dickinson; David M Gundermann; Dillon K Walker; Paul T Reidy; Michael S Borack; Micah J Drummond; Mohit Arora; Elena Volpi; Blake B Rasmussen Journal: J Nutr Date: 2014-09-03 Impact factor: 4.798
Authors: Abbie E Smith-Ryan; Katie R Hirsch; Hannah E Saylor; Lacey M Gould; Malia N M Blue Journal: J Athl Train Date: 2020-09-01 Impact factor: 2.860